3/31
08:16 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Neutral
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
3/31
08:00 am
cgon
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
Neutral
Report
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
3/28
07:00 am
cgon
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
Low
Report
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
3/26
08:13 pm
cgon
Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? [Yahoo! Finance]
Medium
Report
Is CG Oncology (CGON) Among the Best IPO Stocks to Buy in 2025? [Yahoo! Finance]
3/25
08:18 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
3/24
08:08 am
cgon
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy [Yahoo! Finance]
Medium
Report
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy [Yahoo! Finance]
3/24
08:00 am
cgon
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Medium
Report
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
3/12
08:00 am
cgon
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Low
Report
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
3/7
12:26 pm
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $55.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $55.00 price target on the stock.
2/26
08:30 am
cgon
Best Practices for Operationalizing Global, Early-Phase Oncology Trials, Upcoming Webinar Hosted by Xtalks
Medium
Report
Best Practices for Operationalizing Global, Early-Phase Oncology Trials, Upcoming Webinar Hosted by Xtalks
2/26
08:00 am
cgon
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Low
Report
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
1/10
01:13 pm
cgon
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
1/7
08:50 am
cgon
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Low
Report
CG Oncology, Inc. (NASDAQ: CGON) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.